The pathway inhibitor LY294002 blocks TEAD4-induced migration, invasion, and expression of EMT-related markers, proving that TEAD4 is not only an effective prognostic biomarker but also a potential target for treating metastatic BLCA.61 This evidence concerns the gene TEAD4 and bladder transitional cell carcinoma.